Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension

Sudeep R. Aryal, Oleg F. Sharifov and Steven G. Lloyd

Affiliations: 1Dept of Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA. 2Birmingham VA Medical Center, Birmingham, AL, USA.

Correspondence: Steven G. Lloyd, Division of Cardiovascular Disease, Dept of Medicine, University of Alabama at Birmingham, 1808 7th Avenue South, BDB 201, Birmingham, AL 35294-0012, USA. E-mail: slloyd@uabmc.edu

@ERSpublications

This review discusses the role of cardiovascular magnetic resonance in the diagnosis and management of pulmonary hypertension, including current applications and future developments, in comparison to other existing major imaging modalities. http://bit.ly/39RXPb0

Cite this article as: Aryal SR, Sharifov OF, Lloyd SG. Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension. Eur Respir Rev 2020; 29: 190138 [https://doi.org/10.1183/16000617.0138-2019].

ABSTRACT Pulmonary hypertension (PH) is a clinical condition characterised by elevation of pulmonary arterial pressure (PAP) above normal range due to various aetiologies. While cardiac right-heart catheterisation (RHC) remains the gold standard and mandatory for establishing the diagnosis of PH, noninvasive imaging of the heart plays a central role in the diagnosis and management of all forms of PH. Although Doppler echocardiography (ECHO) can measure a range of haemodynamic and anatomical variables, it has limited utility for visualisation of the pulmonary artery and, oftentimes, the right ventricle. Cardiovascular magnetic resonance (CMR) provides comprehensive information about the anatomical and functional aspects of the pulmonary artery and right ventricle that are of prognostic significance for assessment of long-term outcomes in disease progression. CMR is suited for serial follow-up of patients with PH due to its noninvasive nature, high sensitivity to changes in anatomical and functional parameters, and high reproducibility. In recent years, there has been growing interest in the use of CMR derived parameters as surrogate endpoints for early-phase PH clinical trials. This review will discuss the role of CMR in the diagnosis and management of PH, including current applications and future developments, in comparison to other existing major imaging modalities.

Epidemiology, classification and clinical manifestations of pulmonary hypertension

The taskforce for the 6th World Symposium on Pulmonary Hypertension (2019) proposed a modified haemodynamic definition for pulmonary hypertension (PH) of mean pulmonary arterial pressure (PAP) >20 mmHg and defined precapillary PH (also known as pulmonary arterial hypertension (PAH)) by the concomitant presence of mean PAP >20 mmHg, pulmonary vascular resistance (PVR) ≥3 Wood units and pulmonary artery wedge pressure (PAWP) ≤15 mmHg [1]. Clinical PH groups (table 1) previously classified at the 4th World Symposium on PH and endorsed by the European Society of Cardiology (ESC)/European Respiratory Society (ERS) [2] were updated.
|                  | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|------------------|---------|---------|---------|---------|---------|
| **PH category**  | PAH     | Pulmonary venous hypertension due to left-heart disease | PH due to lung disease | PH due to chronic thromboembolism | PH due to multifactorial or miscellaneous cause |
| **Major causes** | Idiopathic Heritable CTD HIV Drug/toxin induced Shunts (CHD) | Left heart disease (left-ventricular systolic and diastolic dysfunction) Valvular heart disease (mitral, aortic) | ILD COPD Sleep apnoea | Chronic thromboembolism | Myeloproliferative disorders Sarcoidosis Glycogen storage disease Chronic haemolytic anaemia Thyroid disease Chronic kidney disease |
| **Diagnostic criteria by RHC** | Mean PAP >20 mmHg PAWP ≤15 mmHg PVR ≥3 Wood units | Mean PAP >20 mmHg PAWP >15 mmHg PVR <3 or ≥3 Wood units | Mean PAP >20 mmHg PAWP ≤15 mmHg PVR ≥3 Wood units | Mean PAP >20 mmHg PAWP ≤15 mmHg PVR ≥3 Wood units | Presence of both precapillary and/or postcapillary PH Mean PAP >20 mmHg; PAWP ≤15 mmHg; PVR ≥3 Wood units or Mean PAP >20 mmHg; PAWP >15 mmHg; PVR <3 or ≥3 Wood units |
| **Major diagnostic findings by CMR** | Aberrant pulmonary veins Shunts | Left ventricular hypertrophy Left ventricular dysfunction Dilated left atrium Valvular disease Pulmonary vein stenosis | Gross fibrosis of the lung parenchyma | Thrombus in the pulmonary vessel | Lymphadenopathy Absence of spleen Focal LGE [sarcoidosis] |
| **Essential diagnostic CMR modality** | Dedicated cardiac views Flow mapping (phase contrast flow velocity and/or 4-D flow analysis) MRA | Short and/or long axis views cine SSFP LGE Valve lesion quantification | Cine SSFP Flow (phase contrast flow velocity or flow analysis) MRA | MRA LGE | |
| **CMR prognostic focus** | Short and/or long axis views cine SSFP Right ventricular function Right ventricle-pulmonary artery coupling |

PAH: pulmonary arterial hypertension; CTD: connective tissue disorder; CHD: congenital heart disease; ILD: interstitial lung disease; COPD: chronic obstructive pulmonary disease; RHC: right-heart catheterisation; PAP: pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; LGE: late gadolinium enhancement; MRA: magnetic resonance angiography; SSFP: steady-state free precession.
PH is characterised by excessive intimal proliferation, fibrosis and severe vasoconstriction in the pulmonary vasculature with resultant pressure overload on the right ventricle. Although the actual prevalence of PH is not certain, data from registries estimate mortality at 6.5 deaths per 1000 000 people with 131 hospitalisations per 100 000 discharges in the United States between 2001 and 2010 [3]. PH is more common amongst women with a median survival of 2.8 years without treatment [4]. There are three defined stages of the disease: asymptomatic compensated, symptomatic compensated and advanced decompensated [5–7]. The clinical manifestations of PH are due to progressive right ventricular failure with symptoms of dyspnoea, fatigue, angina and, in advanced cases, syncope.

Importance of evaluating the right ventricle
Despite the morbidity and mortality associated with PH from right ventricular dysfunction and failure, the focus of management has been primarily on pulmonary circulation (probably because of the availability of medications that cause pulmonary vasodilatation). The three major classes of therapy currently available also specifically target pulmonary circulation. The rationale for this strategy is that improvement in pulmonary haemodynamics would naturally improve the right ventricle as the afterload abates. However, recent studies have cast credible doubt on this theory [8–11]. Two widely accepted observations that have influenced thinking about this are that patients with idiopathic PAH (IPAH) have much better right ventricular function and better clinical course than patients with systemic sclerosis (SSc) despite having similar haemodynamics. Also, despite the improvement in haemodynamics, right ventricular function may continue to deteriorate as evident from the study by VAN DE VEERDOONK et al. [8]. The disease progression in PH is mainly due to two interrelated factors, pulmonary artery non-compliance and right ventricular dysfunction. Therefore, for a true evaluation of the disease process it is crucial to assess both the right ventricle and pulmonary artery (table 1) [12].

Diagnosis of pulmonary hypertension with other existing modalities and their challenges
Right-heart catheterisation (RHC) is the current guideline-recommended gold standard for confirming PH. RHC offers reliable assessment of PAP but fails to provide a comprehensive assessment of the condition of the right ventricle, thereby limiting assessment of vital data such as right ventricle–pulmonary artery coupling and left ventricle–right ventricle interdependence [12]. RHC is invasive with potential for serious complications including bleeding, pneumothorax, pulmonary artery rupture, infection and heart block, especially in the presence of existing conduction abnormalities. Early studies reported a high fatality rate (4.2%, FUSTER et al. [13]) and a major procedure-related complication rate (5.3%, RICH et al. [14]) for RHC. Recent studies indicate that when RHC is performed in experienced centres it is a relatively safe procedure with low risk for major complications (around 1%) and procedure-related mortality (around 0.1%) [15–17]. The higher complication risk is reported when RHC is performed in paediatric patients [16], under general anaesthesia [16], or using the femoral vein route [15, 17] and is likely performed in less experienced medical centres. The Multicenter RepHerral study demonstrated that many newly diagnosed patients with PH referred to an expert centre did not receive RHC as part of their diagnostic procedure and a substantial portion of such patients were misdiagnosed and inappropriately treated [18]. Lack of training, cost and perceptions of complication risks were possible reasons for not performing RHC. This emphasises the need for reliable noninvasive tools for initial screening and management of PH patients.

The current routine noninvasive imaging modality for screening patients with clinical suspicion of PH is a transthoracic echocardiography (ECHO) (figure 1) [2]. Transthoracic ECHO uses the modified Bernoulli
equation for assessing right ventricular systolic pressure (RVSP) by calculating the pressure difference between the right ventricle and the right atrium based on the velocity of the tricuspid regurgitant jet and adding the right atrial pressure [19]. Transthoracic ECHO allows evaluation of right ventricular adaptation to increased afterload, using the right ventricle myocardial performance index (also known as the Tei index) [20]. However, transthoracic ECHO has significant critical limitations as the technique is operator dependent and often fails to provide a reliable assessment of right ventricular function due to the lack of standard geometry to allow use of model assumptions [21]. A study by FISHER et al. [19] looking into the accuracy of transthoracic ECHO in comparison to RHC found transthoracic ECHO estimates of PAP to be accurate in only 50% of patients. The tricuspid annular plane systolic excursion (TAPSE) is a common and widely utilised echocardiographic metric used to approximate right ventricular ejection fraction (RVEF) [22]. TAPSE is easily obtained by M-mode ECHO of the right ventricular annulus, with normal values being >20 mm and markedly reduced in the case of right ventricular dysfunction [23]. However, diagnostic and prognostic values of TAPSE suffer from several prominent limitations [24]. Since it focuses only on a small part of the right ventricular myocardium and is affected by overall heart motion, it cannot be considered a comprehensive surrogate for overall right ventricular function [25]. TAPSE is both angle and load dependent, and this needs to be considered in the case of significant tricuspid regurgitation, when right ventricular base active motion may falsely reflect overall right ventricular contractile function. Due to ventricular interdependence, left ventricular systolic motion may also affect TAPSE [26, 27].

Computed tomography (CT) is another preferred imaging modality for the assessment of PH, due to its excellent spatial and temporal resolution, and quick scan time, which offers a comprehensive evaluation of cardiopulmonary structures [28]. Patients with suspicion of PH routinely undergo non-electrocardiogram (ECG)-gated, contrast-enhanced CT for the evaluation of pulmonary artery and lung parenchyma. In the event of clinical suspicion of pulmonary embolism (PE), an ECG-gated computed tomography angiography (CTA) is performed. ECG-gated CTA can demonstrate signs of right ventricular failure such as right ventricular hypertrophy, abnormal curvature or leftward bowing of the interventricular septum (IVS), right ventricular dilation (often defined as a right ventricle diameter : left ventricle diameter ratio >1:1 at the mid-ventricular level), pericardial effusion and, possibly, even tricuspid regurgitation [5]. A ratio of CT-measured main pulmonary artery transverse diameter : ascending aorta diameter >1:1 at the mid-ventricular level) is also highly indicative of PH, with a 96% positive predictive value [29]. CT can help identify causes for PH, such as parenchymal abnormalities in patients with World Health Organization (WHO) group II disease. Furthermore, multiple significant ground-glass opacities may support the diagnosis of pulmonary capillary haemangiomatosis (PCH) [30]. The presence of oesophageal dilation may hint at scleroderma as the cause of PH and a computed tomography pulmonary angiogram (CTPA) allows for the assessment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) being considered for surgical candidacy [31]. Although ventilation/perfusion (V/Q) scanning is considered as the initial imaging modality of choice, once the diagnosis of CTEPH is suggested, CTPA is commonly used to assess the extent of disease and the subsequent cardiopulmonary changes [32]. It should be noted, however, that CT has limitations, with its inability to provide detailed haemodynamic information being a major drawback. Due to significant radiation exposure, the use of CT in patients who need repeat examinations is also less desirable.

Use of cardiovascular magnetic resonance in management of pulmonary hypertension

Although PH is a disease primarily of the pulmonary vasculature, the most common cause of morbidity and mortality is right ventricular failure. Cardiovascular magnetic resonance (CMR) is a three dimensional (3-D) tomographic technique that is considered to be the gold standard for assessing right ventricular function, volume, mass and structure [20]. CMR, with its inherent properties of high spatial and temporal resolution combined with the fact that it does not rely on patients having favourable acoustic windows, provides the most comprehensive information on the right ventricle. Although the use of CMR in PH goes back more than two decades, it is still considered a novel imaging modality in comparison to the other noninvasive imaging modalities like transthoracic ECHO (figure 1). A common factor resulting in relatively low utilisation of CMR is the inability to provide a reliable estimation of PAP [33, 34], considered to be crucial in the assessment and management of PH. However, recent studies have demonstrated that elevated mean PAP can be predicted by CMR using regression models comprising simple and easy to obtain CMR metrics [35, 36]. A correlation between mean PAP and/or PVR, and multiple CMR-derived metrics has been also reported in many clinical research studies [37–41]. Nevertheless, it has been well established that, in PH, PAP in isolation provides no prognostic information whereas the condition of the right ventricle is what determines survival [42, 43].

Most of the studies on PH have focused on estimating PAP and other parameters derived from pressure without simultaneous emphasis on the right ventricle. This is an incomplete approach as both the right
ventricle and pulmonary artery are affected in PH with a differential influence on outcomes. Therefore, CMR can bridge this gap by evaluating both the right ventricle and the pulmonary artery to provide a comprehensive picture [37, 38, 40, 44, 45]. This approach could be cost-effective as comprehensive CMR has the potential to replace other ancillary imaging modalities.

The presence or absence of specific CMR findings may provide clues as to the cause of PH. The presence of aberrant pulmonary veins or other intracardiac shunt lesions may be suggestive of an aetiology for PAH, whereas left ventricular hypertrophy or dysfunction, or left atrial dilation, may suggest PH due to left-sided congestive heart failure (table 1). CRAWLEY et al. [46] have demonstrated that CMR-measured left atrial volume alone has a 97% sensitivity and 100% specificity in differentiating IPAH from PH due to heart failure with preserved ejection fraction (HFpEF). Similarly, magnetic resonance angiography (MRA) can be used to assess pulmonary vessel pruning seen in IPAH, as well as filling defects in the pulmonary vasculature suggestive of CTEPH [47]. Although MRA generally has lower spatial resolution than CTA, MRA techniques with resolution reasonably comparable to CTA may have the edge over the latter for evaluation of pulmonary vasculature, due to the lack of ionising radiation and nephrotoxic contrast agents [48].

A routine CMR study consists of various gradient-echo and phase contrast cine sequences, and the measurements derived from these provide a detailed assessment of the right ventricle and of right ventricle–pulmonary artery coupling that are essential for a thorough evaluation of PH stage (table 2). Cine CMR (see supplementary material) is a technique that displays cardiac motion in a cine loop after creating multiple sequential images of the heart throughout the cardiac cycle. Due to high tissue contrast between the myocardium and blood on gradient-echo imaging, particularly with steady state free procession (SSFP) imaging (see supplementary material), cyclic changes in cardiac structures (such as chambers and ventricular walls) can be displayed. This in turn allows the quantification of ventricular mass, volumes and wall motion, and thereby provides important information about cardiac function. Cine phase contrast imaging (see supplementary material) acquires a series of velocity-sensitive images within a cardiac cycle and can be used to measure blood flow or tissue motion velocity. In the typical display modes, stationary tissue appears gray on the phase contrast image, while the flowing blood would appear as white or black depending on the direction of the flow relative to the velocity-encoding gradients. The phase contrast technique can also be applied to measure flow velocity in 3-D. The data obtained can be analysed to generate virtual stream lines that represent blood flow within a vessel or cardiac chamber [49, 50]. Four-dimensional (4-D) flow analysis (3-D flow plus time) has been introduced recently for the assessment of pulmonary circulation and for PH diagnostics [51–53], and this may eventually become the preferred method for measuring all forms of vascular flow. Enhanced tissue signal intensity/contrast is achieved by adjusting scan pulse sequences in respect to parameters of myocardium/blood/fat/water T1 and T2 relaxation times, and strength of magnetic field. For a more comprehensive analysis of blood flow and differential

| Physiologic changes assessed by CMR | CMR sequence |
|------------------------------------|--------------|
| Stiffening of the pulmonary artery with gradual increase in pressure at rest, leading to worsening of pulmonary artery compliance and reduced RAC | Cine |
| Right ventricular hypertrophy, progressive right ventricular dilation with leftward shift in IVS or D-septum | Velocity-encoded phase contrast |
| Tricuspid regurgitation due to right ventricular dilation and valve annulus stretch | Cine |
| Increased right ventricular pressure leading to a dilated right ventricle with leftward shift of the interatrial septum | Strain imaging |
| Engorged vena cavae with pericardial effusion | LGE imaging for myocardial scar |
| RAC: relative area change; IVS: interventricular septum; LGE: late gadolinium enhancement. | Cine cardiac structure/function |
| T1-weighted fast spin echo without fat suppression to assess pericardium | T1-weighted fast spin echo without fat suppression to assess pericardium |
| Myocardial oedema imaging with T2 weighted sequences | Myocardial oedema imaging with T2 weighted sequences |
properties of myocardial tissue, dynamic contrast is achieved by adding a contrast agent, usually a water-soluble gadolinium (Gd) chelate.

**Determining prognosis and risk assessment**

CMR provides information on a number of variables associated with prognostication and risk assessment. RVEF is an important CMR measurement for prognosis assessment. VAN DE VEERDONK et al. [8] have shown that RVEF at baseline is a more robust predictor of mortality than PVR. Right ventricular stroke volume (RVSV) is another indicator of right ventricular function and is a prognostic measure, with low RVSV shown to be strongly associated with mortality both at baseline and on treatment [54]. VAN WOLFEREN et al. [55] have shown that RVSV measured by CMR correlates well with 6-min walk test (6 MWT) distances in patients with PAH (p<0.0001), with an increase in RVSV of >10 mL during treatment correlating with a significant improvement in 6 MWT distance of >41 m. Left ventricular end diastolic volume (LVEDV) and right ventricular end diastolic volume (RVEDV) are independent predictors of prognosis in IPAH, with increased mortality seen in patients with reduced values [56].

CMR can assess secondary cardiac changes associated with PH, such as right ventricular dilation (typically defined as a right ventricle : left ventricle diameter >1 in axial images) [57]. Right ventricular hypertrophy, an effect of increased and sustained afterload in PH (defined as right ventricular wall thickness (RVWT) >4 mm), results in higher right ventricular mass (RVM). A right ventricular mass index (RVMI) >59 g·m⁻² (as measured by CMR) is associated with increased mortality in patients with IPAH [10]. A ventricular mass ratio (defined as RVM/left ventricular mass (LVM)) >0.6 has an 84% sensitivity and 71% specificity for the diagnosis of PH [28, 58].

In advanced PH, the conventional rightward-convex ventricular septum is either flattened or bowed during systole towards the left ventricle, resulting in the left ventricle becoming D-shaped and the right ventricle subsequently becoming concentric [59]. The resultant effect of this septal bowing is a reduction in RVEF that has a strong correlation with the measurement of the paradoxical curvature of the IVS and the severity of PH [60]. The presence of pericardial effusion also indicates poor prognosis [61].

Contrast agents can provide additional important diagnostic/prognostic value in a CMR study of PH. After intravenous injection of the contrast agent, it travels between the intravascular space and the interstitial space but does not enter the intracellular space and demonstrates different concentration–time curves in the normal and abnormal myocardium. Compared to healthy cardiac tissues, abnormal myocardium such as infarcted or scarred myocardium tend to retain more contrast on a per-unit-volume basis due to the loss of intact cardiomyocytes and expanded interstitial space [62]. In PH patients, injection of Gd-based contrast agents can produce late gadolinium enhancement (LGE) due to its higher volume of distribution and delayed washout in the regions of scarring or fibrosis, which is often seen at the right ventricular insertion point (RVIP) at the IVS between the right and left ventricles. The results of various studies have suggested a significant inverse correlation between the degree of RVIP LGE and RVEF and haemodynamics [63–66]. RVIP LGE may therefore be useful as a prognostic marker and an indicator of more advanced right ventricular changes, especially in patients with PAH and, as such, it may assist in risk stratification and enabling appropriate therapy to be administered promptly [67]. The volume of LGE, which correlates well with RVM, volume, remodelling and dysfunction, also has prognostic value [67]. A higher degree of enhancement suggests poorer right ventricular performance, which in turn is associated with poorer prognosis [65, 68]. A Gd-based contrast agent can also be used to assess myocardial perfusion reserve in response to pharmacologically-induced stress (e.g. by adenosine) or exercise. It has been reported that reduced right and left ventricular myocardial perfusion reserves are associated with elevated mean PAP in PAH patients and are closely correlated to increased right ventricular workload and right ventricular dysfunction [69].

The use of a Gd-based contrast agent is considered generally safe. The most common side effects are mild and include headaches, nausea, itchiness, dizziness, vomiting and inflammation. However, in very rare cases, Gd-chelate contrast agents can produce a rare disease known as nephrogenic systemic fibrosis (NSF) in the presence of severe kidney failure [70]. Some of the Gd-chelate contrast agents (group 2 agents, e.g. gadobenate dimeglumine and gadoteridol) are much less likely to cause NSF in patients with chronic kidney disease [71] and care should therefore be exercised in the choice of appropriate contrast agent in respect to patient renal function. Recently, native T1-mapping has been introduced as an alternative technique to LGE for characterisation of the myocardium without the use of contrast agents [72]. T1-mapping quantifies the T1 relaxation time per pixel of tissue and T1-values increase when the heart is affected by oedema and fibrosis [73, 74]. SPRUIJT et al. [75] have reported that native T1-values for the interventricular insertion regions are significantly increased in precapillary PH and are related to disease severity. In patients with postcapillary PH due to HFpEF, NITSCH et al. [76] have shown that interstitial...
expansion of the anterior right ventricular interventricular insertion, as detected by CMR T1-mapping, reflects haemodynamic alterations and is independently associated with long-term outcome.

Cardiac output in phase contrast CMR has been shown to be an independent predictor for prognosis, with the presence of slow flow in the main pulmonary artery associated with adverse prognosis and mortality [45]. A number of phase contrast CMR measured indices of pulmonary artery haemodynamics, including flow and flow velocity metrics, have been reported to correlate with mean PAP and PVR [37, 38, 77], and thus have important diagnostic/prognostic values in PH patient management. Interestingly, a study by Gan et al. [78] has shown that the degree of pulmonary artery relative area change (RAC) is the strongest predictor of death (more powerful than 6 MWT, PAP, cardiac output and right atrial pressure), with a value \( \leq 16\% \) being associated with poor prognosis. Pulmonary artery RAC (or pulsatility), a noninvasive measure of pulmonary artery stiffness, is defined as: (maximal pulmonary artery area – minimum pulmonary artery area)/minimum pulmonary artery area [40, 78–80]. Area change (AC) is defined as: maximal area – minimum area, with the maximal and minimal pulmonary artery cross-sectional areas traced from CMR cine images. Swift et al. [44] have subsequently demonstrated that both RAC and AC are good predictors of adverse outcome in PH. Pulmonary artery pulse-wave velocity (PWV), another noninvasive measure of pulmonary artery stiffness, is increased in PH patients and has an important prognostic value [81, 82]. CMR exercise stress offers great potential in clinical practice to noninvasively assess vascular function in the right ventricle and the pulmonary artery. Cardiac output and PWV increase in response to acute moderate exercise in healthy subjects and PH patients, while RAC decreases; however, PWV appears to increase more in PH patients [83, 84]. In PAH patients, stroke volume increased in WHO functional class I and decreased in WHO functional class II in response to exercise [85]. Thus, exercise CMR stratifies patients initially perceived as having a low risk of mortality into different degrees of right ventricular inotropic reserve, with a reduced stroke volume during exercise becoming a contributing factor to increased risk of decompensation [83]. However, the prognostic utility of these CMR-derived variables, including RVEF, needs to be validated in large prospective trials as their promise has been assessed primarily based on retrospective analysis.

### Determining response to therapy

Although RHC will continue to be the gold standard test for initial diagnosis of PAH, the role of CMR in serial monitoring to determine treatment response is growing. CMR can be utilised during follow-up to estimate the measure of response to therapy and the degree of clinical worsening, as well as to assist with treatment decisions. Traditionally RHC has been favoured as the gold standard to assess the response to therapy. However, recent studies suggest that CMR may also have value, possibly even more so than RHC due to its noninvasive nature and ability to provide a comprehensive evaluation of both the right ventricle and the pulmonary artery (thus providing an accurate assessment of disease progression) [86–88]. For example, an increase in pulmonary artery RAC of \( >10\% \) signifies a good response to pulmonary vasodilator therapy [44, 89].

A pilot study by Jardim et al. [89] has shown (in 19 patients with IPAH) that CMR evaluation of the RAC in the main pulmonary artery (immediately after a RHC procedure) correlates well with vasodilator response (\( p=0.01 \)) and that an RAC cut-off value of 10% allows responders to be distinguished from nonresponders with 100% sensitivity and 56% specificity. The ability of CMR to reliably evaluate right ventricular function, mass and size has been used in endpoints in trials using sildenafil [90] and bosentan [11]. Furthermore, the large prospective EURO-MR study has shown that CMR measurements taken at baseline and at subsequent follow-up provide credible information about patient response to vasodilator therapy [91].

In a study by Roelveld et al. [92], CMR has been performed to assess treatment response in 11 IPAH patients on continuous intravenous epoprostenol over 1 year. Patients showed significant improvement in RVSV during the first 4 months of treatment, with good correlation observed between the improvement in RVSV and increase in 6 MWT. In a study by Allanore et al. [93], involving 18 patients with PAH due to SSc who were treated with bosentan, CMR in combination with tissue Doppler ECHO showed improvement in myocardial perfusion and myocardial function after 4 weeks of treatment. CMR was also used in a study by Resnek et al. [94] to evaluate right and left ventricular remodelling in 17 patients with CTEPH at 4 months following pulmonary endarterectomy. Post-surgery CMR showed normalisation of right and left ventricular volume with leftward ventricular septal bowing.

### Using cardiovascular magnetic resonance measurements as trial endpoints

The change in 6 MWT has been the most widely used primary endpoint in many PAH clinical trials, mainly due to its ease of use, noninvasive nature and low cost. It has also been used for regulatory approval of therapies for patients with PAH. However, the validation of 6 MWT is so far restricted to
| Study | Type of study | Patients n | Aim | CMR endpoints | Key results summary |
|-------|--------------|------------|-----|---------------|---------------------|
| Van Wolferen [10] (2007) | Prospective observational study | 64 | Investigate the relationship between right ventricular structure, function and survival in IPAH | CI RSVI RVMI LVMI RWT LVWT RVEF LVEF RVEDVI LVEDVI | The following are strong independent predictors of mortality and treatment failure: large right ventricular volume; low stroke volume; reduced left ventricular volume |
| Van de Veerdonk [8] (2011) | Prospective observational study | 110 | Examine the relationship between changes in PVR, RVEF and survival in patients with PAH under PAH-targeted therapies | RVEDVI RVESVI RVEF LVEDVI LVESVI LVEF RVSVI | Loss of right ventricular function is associated with a poor outcome, irrespective of any changes in PVR |
| Wilkins [103] (2005), SERAPH | Randomised controlled trial | 26 | Compare the effect of adding sildenafil, a PDE-5i, to bosentan, an ERA (and the conventional treatment) in PAH | RVM | RVM decreased with addition of sildenafil to bosentan (mean −8.8 g versus −3 g; p=0.142) |
| Wilkins [104] (2010), SiPHT | Randomised controlled trial | 42 | Assess the therapeutic value of simvastatin in patients with PAH | RVM | Simvastatin added to conventional therapy produced a small and transient early reduction in RVM but this was not sustained over 12 months |
| Roeleveld [92] (2004) | Prospective observational study | 11 | Assess changes in main pulmonary artery flow, as well as RVM and volumes, in patients with PH during epoprostenol therapy | RVM RVEDV | No significant changes noted in either parameter |
| Van Wolferen [105] (2006) | Prospective observational study | 15 | Investigate whether the addition of sildenafil reverses right ventricular remodelling and improvement in right ventricular function in PAH treated with bosentan | RVM RVEF RVEDV | Addition of Sildenafil to bosentan significantly decreased RVM (p<0.01) and increased RVEF (p<0.05) with no significant change in RVEDV |
| Chin [11] (2008) | Prospective observational study | 16 | Investigate changes in CMR measurements in PAH treated with bosentan and compare cardiac MRI results with other known markers of prognosis, including RHC and 6 MWT | RVEF RVEDV RVSV | No significant changes noted with bosentan therapy |
| Peacock [91] (2014), EURO-MR | Prospective observational study | 91 | Assessment of right ventricular function using CMR to determine response to therapy (ERA or PDE-5i) and to monitor disease progression in PH | RVEDVI RVSVI RVEF RVM Significant improvement noted in RVEF (p<0.001) and RVSVI (p<0.0001) | |
| Van de Veerdonk [106] (2017) | Retrospective study | 80 | Assess the impact of upfront combination therapy (ERA+PDE-5i) on right ventricular volume compared with monotherapy (ERA or PDE-5i) in PAH | RVEDV RVESV RVM RVEF Relative RWT | Right ventricular volumes, calculated right ventricular wall stress and RVEF improved after combination therapy (p<0.001) but remained unchanged after monotherapy |
| Hassoun [107] (2015), ATPAHSS–O | Prospective, multicentre study | 24 | Evaluate the effect of upfront combination therapy with ambrisentan and tadalafil on left and right ventricular function in patients with SSc-PAH | RVM | Significantly greater reductions in RVM noted with combination therapy (28.0 g versus 32.5 g; p<0.05) |
patients with IPAH and patients with PAH due to connective tissue disorder (CTD). 6 MWT is also affected by many variables, mainly comorbidities, age, muscular training, motivation and mood, and therefore may not provide a true reflection of cardiac condition. Furthermore, 6 MWT loses its sensitivity in patients with mild symptoms and a considerable baseline walking distance, but with a high burden of disease, as observed in a bosentan trial in WHO functional group 2 PH patients [95–97]. 6 MWT also loses its reliability in patients already on a background therapy, as shown in the Pulmonary Hypertension Response to Tadalafil (PHIRST) trial, where patients treated with tadalafil in combination with a background therapy showed only a modest improvement in 6 MWT when compared to treatment naïve patients who received tadalafil alone [98]. This aspect is essential to consider when utilising 6 MWT as a primary endpoint for studies involving an "add-on" therapy in addition to an existing background therapy. Here, it becomes paramount to use metrics other than 6 MWT with sufficient sensitivity to capture additional treatment effects due to the new agents.

In CMR studies of PH, 6 MWT or its change due to treatment correlate with both routine CMR metrics (including RVEF and LVEDV, RVEF and RVSV [11], and RVSV [55]) and more sophisticated metrics (such as percentage of myocardial fibrosis [99]). CMR has the best inter-study reproducibility of all imaging modalities for the measurement of right ventricular chamber volume and mass, making it a crucial tool for clinical trials in PAH [100]. Due to these factors, the focus for PAH trial endpoints has been shifting away from the traditional measurement of 6 MWT, which suffers from the inherent limitations mentioned above, to a more reliable, reproducible assessment of the right ventricle by CMR [101].

Studies showing good correlation between RHC-measured PVR and CMR derived parameters suggest the possibility of using CMR data as a surrogate for RHC, especially in serial follow-up in patients with PAH to assess progress or response to therapy [102]. Since the mortality associated with PH is due to progressive right ventricular dysfunction, it becomes essential to have a primary endpoint which provides a better physical characterisation of the right ventricle at baseline and with response to therapy. For instance, in the SERAPH (Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension) study of patients with IPAH, change in RV measured by CMR is considered as the primary endpoint [103]. Other complete and ongoing clinical studies/clinical trials utilising CMR endpoints are described in table 3.

Advantages and disadvantages of cardiovascular magnetic resonance in pulmonary hypertension
Whereas other imaging modalities have limited capabilities in assessing PH, CMR with its comprehensive measurements can become a “one-stop shop” for evaluation of PH and its therapeutic management. Since the condition of the right ventricle is what determines survival in PH, CMR with its robust assessment of right ventricular structure and function compares well to RHC. Although RHC is considered to be the gold standard for haemodynamic evaluation, CMR can potentially deliver a reliable and noninvasive estimation of PAP and pulmonary blood volume, thereby allowing examination of the right ventricle and

### Table 3 Continued

| Study          | Type of study                  | Patients n | Aim                                                                 | CMR endpoints                                                                 | Key results summary |
|----------------|--------------------------------|------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------|
| REPAIR (Clinicaltrials.gov NCT02310672) | Prospective, multicentre, single-arm study | In progress | Assess the effect of macitentan on right ventricular and haemodynamic properties (at baseline and 26 weeks) in patients with symptomatic PAH | Changes in RVSV Ventriculo-arterial coupling measured by CMR | In progress |
| REPLACE (Clinicaltrials.gov NCT02829034) | Multicentre, randomised controlled trial versus placebo | In progress | Assess the effectiveness of riociguat as a replacement for PDE-5i therapy in PAH | Change in RVEF measured by CMR | In progress |

IPAH: idiopathic PAH; CI: cardiac index; RVM: right ventricular mass; RVMI: right ventricular mass index; LVMI: left ventricular mass index; RVWT: right ventricular wall thickness; LWWT: left ventricular wall thickness; RVEF: right ventricular ejection fraction; LVEF: left ventricular ejection fraction; RVEDV: right ventricular end diastolic volume; RVEDVI: right ventricular end diastolic volume index; LVEDVI: left ventricular end diastolic volume index; PVR: pulmonary vascular resistance; LVESVI: left ventricular end systolic volume index; RVESV: right ventricular end systolic volume; RVESVI: right ventricular end systolic volume index; RVSV: right ventricular stroke volume; RVSVI: right ventricular stroke volume index; PDE-5i: phosphodiesterase type-5 inhibitor; ERA: endothelin receptor antagonist; MRI: magnetic resonance imaging; RHC: right-heart catheterisation; 6MWT: 6-min walk test; SSc-PAH: systemic sclerosis associated PAH.

https://doi.org/10.1183/16000617.0138-2019
pulmonary artery as one unit in order to provide a detailed understanding of disease process and progression, as well as to provide assistance with management (table 4). However, despite extensive research there are still limited data on the clinical use of pulmonary circulation imaging by CMR in PH. Therefore, it is difficult to compare the utility of CMR, ECHO and CT in this respect. However, CMR would avoid the limitations of ECHO (due to a poor echo window) in a substantial patient cohort with advanced lung disease [108]. Overall diagnostic and prognostic values of the major noninvasive imaging modalities in PH have not been comprehensively compared. In one single-centre retrospective study (n=81), CMR and ECHO had greater diagnostic utility than CT in assessment of PAH in patients with CTD, while CMR also provided prognostic value [109]. Recent studies have found that despite correlation

| Parameter | CMR | ECHO | CT (incl. CTA) | RHC |
|-----------|-----|------|---------------|-----|
| **Initial diagnosis and confirmation** | ++ | ++ | (may suggest) | (may suggest) |
| **Aetiology** | ++ | ++ | (may suggest) | (gold standard) |
| | | | | (especially in CTEPH and ILD-related PH) |
| **Right ventricle variables** | | | | |
| **Pressure** | +++ | ++ | -- | +++ |
| **Ejection fraction** | +++ | ++ | -- | -- |
| **Mass** | +++ | -- | ++ | -- |
| **Right ventricular remodelling** | +++ | ++ | -- | -- |
| **Septal curvature** | +++ | ++ | -- | -- |
| **Pericardial effusion** | ++ | +++ | -- | -- |
| **TAPSE** | -- | +++ | -- | -- |
| **Ventricular–arterial coupling** | +++ | -- | -- | -- |
| **Right atrial variables** | | | | |
| **Area/volume** | ++ | ++ | + | -- |
| **Pressure** | -- | + | -- | +++ |
| **Pulmonary artery variables** | | | | |
| **Pressure** | ++ | ++ | -- | -- |
| **RAC/pulsatility** | +++ | + | -- | -- |
| **Distensibility** | +++ | ++ | -- | -- |
| **Quantitative blood flow** | +++ | -- | -- | -- |
| **Strengths** | Gold standard for assessing ventricular mass and structure | Readily available preferred imaging modality for first screening | Good for evaluation of aetiologies [especially CTEPH and ILD-related PH] | Gold standard for confirmation of PH |
| **Limitations** | Limited availability | Limited role for confirmation/assessment of aetiology | Significant amount of radiation involved | Provides no information about the morphology and function of the right ventricle |

**CMR**: cardiovascular magnetic resonance; **CT**: computed tomography; **CTA**: computed tomography angiography; **RHC**: right-heart catheterisation; **CTEPH**: chronic thromboembolic pulmonary hypertension; **ILD**: interstitial lung disease; **WHO**: World Health Organization; **TAPSE**: tricuspid annular plane systolic excursion; **RAC**: relative area change; **ECHO**: echocardiography; **ECG**: electrocardiogram. **#: CT/CTA can assess these variables if ECG-gating is employed.**
between ECHO metrics for evaluation of right ventricular systolic function (e.g. TAPSE, right ventricular fractional area change (RAC) and the Tei index) and CMR-derived RVEF, ECHO metrics show limited accuracy in predicting improvement or deterioration of right ventricular systolic function during serial follow-up assessment in PAH patients [110, 111]. These studies indicate that CMR remains the gold standard for the serial assessment of right ventricular systolic function.

In comparison to ECHO or CT, CMR has a number of advantages due to its overall excellent spatial resolution, lack of the need for geometric assumptions for ventricle assessment, reproducibility and lack of ionising radiation. With a single brief breath hold and using cardiac gating, multiple scans can be obtained without the problems of respiratory motion artifacts. Despite these obvious attractive features, CMR suffers from limited temporal resolution in comparison to ECHO, making it less suitable for dynamic measurements. Longer scan time (albeit getting shorter with advancement in technology) and incompatibility with magnetic objects (i.e. metallic hardware, implants, clips and pacemakers etc) also limit its use (table 4), although the latter is also becoming less problematic with the advent of magnetic resonance conditional implanted electronic devices. Furthermore, the accessibility of CMR for widespread utilisation is somewhat limited due to cost, the expertise required to perform scans and analyse images, and limited familiarity about its capabilities among non-imaging-specialist physicians. Further advances in technology and education may help to increase its use.

**Conclusion**

The mounting use of CMR in providing a comprehensive assessment of the right ventricle and pulmonary artery for the global management of PH is encouraging. Despite higher costs, limited availability and the requirement for trained expertise, CMR stands out distinctly in comparison to other conventional imaging tools like ECHO in providing not only detailed anatomic data but also additional vital information related to diagnosis, prognostication, disease progression and response to therapy. As the technology continues to evolve and access becomes more widespread, CMR has the potential to emerge as the noninvasive imaging modality of choice for comprehensive evaluation of PH. A profound acceptance of this significant but under-utilised technology requires a widespread understanding of its immense potential, the realisation of the importance of the right ventricle and not just PAP in the optimal management of PH, and development of standardised protocols and unitisation in multicenter PH trials. The implementation of standardised protocols could lead to shorter scan times with a reduction in cost and would ultimately make the imaging technology more realistic for broader use.

Conflict of interest: None declared.

**References**

1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019; 53: 1801913.
2. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2015; 46: 903–975.
3. Goldberg AB, Mazur W, Kaira DK. Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies. *Cardiovasc Diagn Ther* 2017; 7: 405–417.
4. Talwar A, Garcia JGN, Tsai H, et al. Health disparities in patients with pulmonary arterial hypertension: a blueprint for action. An official American Thoracic Society statement. *Am J Respir Crit Care Med* 2017; 196: e32–e47.
5. Pena E, Dennie C, Veinot J, et al. Pulmonary hypertension: how the radiologist can help. *Radiographics* 2012; 32: 9–32.
6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. *N Engl J Med* 2004; 351: 1655–1665.
7. Lang IM, Plank C, Sadushi-Kolici R, et al. Imaging in pulmonary hypertension. *JACC Cardiovasc Imaging* 2010; 3: 1287–1295.
8. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. *J Am Coll Cardiol* 2011; 58: 2511–2519.
9. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: D73–D81.
10. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. *Eur Heart J* 2007; 28: 1250–1257.
11. Chin KM, Kingman M, de Lemos JA, et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. *Am J Cardiol* 2008; 101: 1669–1672.
12. Ibrahim el SH, White RD. Cardiovascular magnetic resonance for the assessment of pulmonary arterial hypertension: toward a comprehensive CMR exam. *Magn Reson Imaging* 2012; 30: 1047–1058.
13. Foster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation* 1984; 70: 580–587.
14. Rich S, Duntscher DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. *Ann Intern Med* 1987; 107: 216–223.
15. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *J Am Coll Cardiol* 2006; 48: 2546–2552.

https://doi.org/10.1183/16000617.0138-2019
Sahay S, Tonelli AR. Pericardial effusion in pulmonary arterial hypertension. Roeleveld RJ, Marcus JT, Faes TJ, Giordano J, Khung S, Duhamel A, Abd El Rahman MY, Hui W, Dsebissowa F, Sieren MM, Berlin C, Oechtering TH, Barker AJ, Roldan-Alzate A, Entezari P, et al. Four-dimensional flow assessment of pulmonary artery flow and wall shear stress in adult pulmonary arterial hypertension: results from two institutions. Magn Reson Med 2015; 73: 1904–1913.

Sieren MM, Berlin C, Oechtering TH, et al. Comparison of 4D Flow MRI to 2D Flow MRI in the pulmonary arteries in healthy volunteers and patients with pulmonary hypertension. PLoS One 2019; 14: e0224121.

Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252–260.

van Wolferen SA, van de Veerdonk MC, Mauritz GJ, et al. Clinically significant change in stroke volume in pulmonary hypertension. Chest 2011; 139: 1003–1009.

Mauritz GJ, Kind T, Marcus JT, et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest 2012; 141: 935–943.

Goerne H, Batra K, Rajiah P. Imaging of pulmonary hypertension: an update. Cardiovasc Diagn Ther 2018; 8: 279–296.

Giordano J, Khung S, Duhamel A, et al. Lung perfusion characteristics in pulmonary arterial hypertension (PAH) and peripheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): dual-energy CT experience in 31 patients. Eur Radiol 2017; 27: 1631–1639.

Abd El Rahman MY, Hui W, Desbissowa F, et al. Quantitative analysis of paradoxical interventricular septal motion following corrective surgery of tetralogy of fallot. Pediatr Cardiol 2005; 26: 379–384.

Roeveke RD, Marcus JT, Faes TJ, et al. Interventricular septal configuration at MR imaging and pulmonary arterial pressure in pulmonary hypertension. Radiology 2005; 234: 710–717.

Sahay S, Tonelli AR. Pericardial effusion in pulmonary arterial hypertension. Palm Circ 2013; 3: 467–477.

Tseng W-YI, Su M-YM, Tseng Y-HE. Introduction to cardiovascular magnetic resonance: technical principles and clinical applications. Acta Cardiol Sin 2016; 32: 129–144.

Junqueira FP, Macedo R, Coutinho AC, et al. Myocardial delayed enhancement in patients with pulmonary hypertension and right ventricular failure: evaluation by cardiac MRI. Br J Radiol 2009; 82: 821–826.

Sanz J, Dellegrottaglie S, Kariisa M, et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol 2007; 100: 731–735.

McCann GP, Gan CT, Beek AM, et al. Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. AJR Am J Roentgenol 2007; 188: 349–355.

Blyth KG, Groenning BA, Martin TN, et al. Contrast-enhanced cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 2005; 26: 1993–1999.

Freed BH, Gomberg-Maitland M, Chandra S, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson 2012; 14: 11.

Taylor AJ, Salerno M, Dharmakumar R, et al. T1 mapping: basic techniques and clinical applications. JACC Cardiovasc Imaging 2016; 9: 67–81.

Vogel-Clausen J, Skrok J, Shehata ML, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 2011; 258: 119–127.

Kitajima K, Maeda T, Watanabe S, et al. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012; 19: 806–811.

Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3–5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol. AJR Am J Roentgenol 2015; 205: 469–478.

Ferreira VM, Piechnik SK, Dall’Armellina E, et al. T1(t) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging 2013; 6: 1048–1058.

Burt JR, Zimmerman SL, Kamel IR, et al. Myocardial T1 mapping: techniques and potential applications. Radiographics 2014; 34: 377–395.

Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 2013; 99: 932–937.

Spruijt OA, Vissers L, Bogaard HJ, et al. Increased native T1-values at the interventricular insertion regions in precapillary pulmonary hypertension. Int J Cardiovasc Imaging 2016; 32: 451–459.

Nitsch C, Kammerlander AA, Binder C, et al. Native T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fraction. Eur Heart J Cardiovasc Imaging 2019; in press [https://doi.org/ 10.1093/ehjci/jez221].

Freed BH, Collins JD, Francois CJ, et al. MR and CT imaging for the evaluation of pulmonary hypertension. JACC Cardiovasc Imaging 2016; 9: 715–732.

Gan CT, Lankhaar JW, Westerhof N, et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007; 132: 1906–1912.

Toshner MR, Gopalan D, Suntharalingam J, et al. Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2010; 29: 610–615.

Ray JC, Burger C, Mergo P, et al. Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. Int J Cardiovasc Imaging 2019; 35: 1881–1892.

Ibrahim EL, Shaffer JM, White RD. Assessment of pulmonary artery stiffness using velocity-encoding magnetic resonance imaging: evaluation of techniques. Magn Reson Imaging 2011; 29: 966–974.

Agoston-Coldea L, Lupu S, Mocan T. Pulmonary artery stiffness by cardiac magnetic resonance imaging predicts major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. Sci Rep 2018; 8: 14447.

Forouzan O, Warczeczyw J, Wieben O, et al. Non-invasive measurement using cardiovascular magnetic resonance of changes in pulmonary artery stiffness with exercise. J Cardiovasc Magn Reson 2015; 17: 109.
Exercise-induced changes in pulmonary artery stiffness in pulmonary hypertension. *Front Physiol* 2019; 10: 269.

Goransson C, Veijsstrup N, Carlsen J. Exercise cardiovascular magnetic resonance imaging allows differentiation of low-risk pulmonary arterial hypertension. *J Heart Lung Transplant* 2019; 38: 627–635.

Mousseaux E, Tasu JP, Jolivet O, et al. Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging—preliminary experience. *Radiology* 1999; 212: 896–902.

Abolmaali N, Seitz U, Esmaeili A, et al. Evaluation of a resistance-based model for the quantification of pulmonary arterial hypertension using MR flow measurements. *J Magn Reson Imaging* 2007; 26: 646–653.

Garcia-Alvarez A, Fernandez-Friery L, Mirelis JG, et al. Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. *Eur Heart J* 2011; 32: 2438–2445.

Jardin C, Rochitte CE, Humbert M, et al. Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study. *Eur Respir J* 2007; 29: 476–481.

Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation* 2003; 108: 2066–2069.

Peacock AJ, Crawley S, McLure L, et al. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. * Circ Cardiovasc Imaging* 2014; 7: 107–114.

Roedelvåg RJ, Vond-Koonstra A, Marcus JT, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. *Chest* 2004; 125: 572–579.

Allanore Y, Meune C, Vignoux O, et al. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. *J Rheumatol* 2006; 33: 2464–2469.

Reesink HJ, Marcus JT, Tulevski II, et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. *J Thorac Cardiovasc Surg* 2007; 133: 58–64.

Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. *Vascul Pharmacol* 2005; 43: 36–39.

Gaine S, Simonneau G. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. *Eur Respir Rev* 2013; 22: 487–494.

Galí N, Rubín LJ, Hoepfer MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *The Lancet* 2008; 371: 2093–2100.

Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *J Heart Lung Transplant* 2011; 30: 632–643.

Bessa LG, Junqueira FP, Bandeira ML, et al. Pulmonary arterial hypertension: use of delayed contrast-enhanced cardiovascular magnetic resonance in risk assessment. *Arq Bras Cardiol* 2013; 101: 336–343.

Hassoun PM, Nikkho S, Rosenzweig EB, et al. Updating clinical endpoint definitions. *Pulm Circ* 2013; 3: 206–216.

Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. *Am Heart J* 2007; 153: 1037–1047.

McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. *J Am Coll Cardiol* 2009; 54: S97–S107.

Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. *Am J Respir Crit Care Med* 2005; 171: 1292–1297.

Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. *Am J Respir Crit Care Med* 2010; 181: 1106–1113.

van Wolderen SA, Boonstra A, Marcus JT, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. *Heart* 2006; 92: 1860–1861.

van de Veerdonk MC, Huis In VTA, Marcus JT, et al. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension. *Eur Respir J* 2017; 49: 1700007.

Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2015; 192: 1102–1110.

Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med* 2003; 167: 735–740.

Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. *J Rheumatol* 2012; 39: 1265–1274.

Sato T, Tsujiyo I, Ohira H, et al. Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension. *PLoS One* 2017; 12: e0187806.

Spruit OA, DiPasqua MC, Bogaard HJ, et al. Serial assessment of right ventricular systolic function in patients with precapillary pulmonary hypertension using simple echocardiographic parameters: a comparison with cardiac magnetic resonance imaging. *J Cardiol* 2017; 69: 182–188.